Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs ... on the Nasdaq under the 'MTSR' symbol. The filing – given a $ ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid ...

Conversations about and treatments for obesity are improving. Many obesity support organizations offer resources, news, and platforms for connection for those with obesity. Some organizations list ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Instituto Nacional de Salud Pública, Av. Universidad No. 655. Col. Sta. Ma. Ahuacatitlan, Cuernavaca, Morelos, CP. 62100, Mexico Among the main drivers causing this shift in obesity prevalence is a ...

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products ...

Walt Disney ( N/A ) sharply outperformed Wall Street’s quarterly earnings estimates on Wednesday, with results buoyed by the ...

England is lumbering towards an epidemic of obesity. One in five people is classified as obese, a proportion which has tripled in 20 years. An astonishing 58 per cent of the adult population is ...